GlycoMimetics Inc  

(Public, NASDAQ:GLYC)   Watch this stock  
Find more results for GLYC
-0.52 (-3.51%)
Real-time:   10:26AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 14.19 - 15.20
52 week 3.82 - 16.94
Open 15.06
Vol / Avg. 96,015.00/437,625.00
Mkt cap 468.90M
P/E     -
Div/yield     -
EPS -1.34
Shares 32.72M
Beta 3.21
Inst. own 94%
Sep 8, 2017
GlycoMimetics Inc at BioCentury NewsMakers in the Biotech Industry Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin - -171945.10%
Operating margin - -172505.30%
EBITD margin - -171475.40%
Return on average assets -41.13% -70.03%
Return on average equity -44.33% -83.96%
Employees 42 -
CDP Score - -


9708 Medical Center Drive
United States - Map
+1-240-2431201 (Phone)
+1-240-2431018 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.

Officers and directors

M. James E. Barrett Ph.D. Chairman of the Board
Age: 74
Bio & Compensation  - Reuters
Rachel K. King President, Chief Executive Officer, Founder, Director
Age: 55
Bio & Compensation  - Reuters
Brian Hahn Chief Financial Officer
Age: 40
Bio & Compensation  - Reuters
John Magnani Ph.D. Chief Scientific Officer, Vice President - Research, Director
Age: 62
Bio & Compensation  - Reuters
Helen M. Thackray M.D. Vice President - Clinical Development, Chief Medical Officer
Age: 46
Bio & Compensation  - Reuters
Patricia S. Andrews Director
Bio & Compensation  - Reuters
Mark Alan Goldberg M.D. Director
Age: 62
Bio & Compensation  - Reuters
Daniel M. Junius Director
Age: 64
Bio & Compensation  - Reuters
Scott Koenig M.D., Ph.D. Director
Age: 64
Bio & Compensation  - Reuters
Timothy R. Pearson Director
Age: 49
Bio & Compensation  - Reuters